Work is ongoing to identify and develop new HSP90 inhibitors with improved pharmacological properties. The modulation of client protein levels has been demonstrated in animal models and cancer patients following systemically well-tolerated exposure to the HSP90 inhibitor 17AAG, which is the first in its class. The use of HSP90 inhibitors has proven invaluable at a basic level in probing the complex cellular functions of this chaperone. Highly specific inhibitors of HSP90 have been identified that redirect its chaperoning activity and decrease cellular levels of the many cancer-related client proteins that depend on it for their function. The essential chaperoning functions of HSPs are subverted during oncogenesis to make malignant transformation possible and to facilitate rapid somatic evolution.įunctioning as biochemical buffers for the numerous genetic lesions that are present within tumours, chaperones, especially HSP90, allow mutant proteins to retain or even gain function while permitting cancer cells to tolerate the imbalanced signalling that such oncoproteins create. Their levels of intracellular expression increase in response to protein-denaturing stressors, such as temperature change, as an evolutionarily conserved response to restore the normal protein-folding environment and to enhance cell survival. Most heat-shock proteins (HSPs) are constitutively expressed molecular chaperones that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth and survival.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |